1. Authorship and Contributions
1.1 Authorship must be based on substantial contributions to study conception, design, data acquisition, analysis, or manuscript preparation.
1.2 Contributors who do not meet authorship criteria should be acknowledged appropriately.
1.3 All authors must approve the final version and accept responsibility for the work.
2. Conflicts of Interest
2.1 Authors must disclose all financial and non-financial relationships, affiliations, and sources of support.
2.2 Conflict of interest statements will be published with the article.
3. Peer Review Responsibilities
3.1 Reviewers must maintain confidentiality of manuscripts under review.
3.2Reviews should be conducted objectively, avoiding personal criticism of authors.
3.3Editors must ensure fair, unbiased, and timely evaluation of submissions.
4. Protection of Research Participants
4.1 Human studies must comply with ethical standards and obtain institutional approval.
4.2 Informed consent must be documented for all participants, with special protections for vulnerable groups.
4.3 Clinical trials must be prospectively registered in a publicly accessible registry
4.4 Patient confidentiality must be safeguarded at all stages of research and publication.
5. Editorial and Publishing Integrity
5.1 Editorial decisions must be independent of commercial influence.
5.2 Mechanisms for corrections, retractions, and expression of concern must be in place.
5.3 Duplicate and redundant publications are strictly prohibited.
6. Scientific Misconduct
6.1 Cases of plagiarism, falsification, fabrication, or unethical conduct will be investigated.
6.2 Actions will be taken in line with COPE guidelines.
7. Journal Policies
7.1 IJMRMA follows transparent policies regarding copyright, licensing, advertising, and sponsorship
7.2 Supplements, partnerships, and collaborations must not compromise editorial independence.
8. Manuscript Preparation and Submission
8.1 Submissions must adhere to ICMJE structure and formatting standards.
8.2 Authors should comply with CONSORT guidelines for clinical trials.
8.3 Systematic reviews must follow the PRISMA statement.
9. IJMRMA Commitment